A Hong Kong-listed company in China has successfully accelerated its drug discovery process by integrating artificial intelligence with traditional laboratory research. Insilico Medicine has reportedly reduced the time required to produce certain drug development candidates to approximately one year. The company's fastest program achieved candidate nomination in nine months, while its typical timeline is around 13 months. This development could lead to faster access to new treatments for patients in need.